Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Geisler, CH, Kolstad, A, Laurell, A, Jerkeman, M, Räty, R, Andersen, NS, Pedersen, LB, Eriksson, M, Nordström, M, Kimby, E, Bentzen, H, Kuittinen, O, Lauritzsen, GF, Nilsson-Ehle, H, Ralfkiaer, E, Ehinger, M, Sundström, C, Delabie, J, Karjalainen-Lindsberg, M-L, Brown, P, Elonen, E & Nordic Lymphoma Group 2012, 'Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur' British Journal of Haematology, bind 158, nr. 3, s. 355-62. https://doi.org/10.1111/j.1365-2141.2012.09174.x

APA

CBE

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg M-L, Brown P, Elonen E, Nordic Lymphoma Group. 2012. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology. 158(3):355-62. https://doi.org/10.1111/j.1365-2141.2012.09174.x

MLA

Vancouver

Author

Geisler, Christian H ; Kolstad, Arne ; Laurell, Anna ; Jerkeman, Mats ; Räty, Riikka ; Andersen, Niels S ; Pedersen, Lone B ; Eriksson, Mikael ; Nordström, Marie ; Kimby, Eva ; Bentzen, Hans ; Kuittinen, Outi ; Lauritzsen, Grete F ; Nilsson-Ehle, Herman ; Ralfkiaer, Elisabeth ; Ehinger, Mats ; Sundström, Christer ; Delabie, Jan ; Karjalainen-Lindsberg, Marja-Liisa ; Brown, Peter ; Elonen, Erkki ; Nordic Lymphoma Group. / Nordic MCL2 trial update : six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. I: British Journal of Haematology. 2012 ; Bind 158, Nr. 3. s. 355-62.

Bibtex

@article{d331808a50804fdfa791834a904cb5c9,
title = "Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur",
abstract = "Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60{\%} event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70{\%} of patients with low-intermediate MIPI-B were alive at 10 years, but only 23{\%} of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at www.isrctn.org as ISRCTN 87866680.",
keywords = "Aged, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cyclophosphamide, Cytarabine, Disease-Free Survival, Etoposide, Female, Hematopoietic Stem Cell Transplantation, Humans, Immunotherapy, Lymphoma, Mantle-Cell, Male, Melphalan, Middle Aged, Podophyllotoxin, Prognosis, Recurrence, Survival Rate, Transplantation, Autologous",
author = "Geisler, {Christian H} and Arne Kolstad and Anna Laurell and Mats Jerkeman and Riikka R{\"a}ty and Andersen, {Niels S} and Pedersen, {Lone B} and Mikael Eriksson and Marie Nordstr{\"o}m and Eva Kimby and Hans Bentzen and Outi Kuittinen and Lauritzsen, {Grete F} and Herman Nilsson-Ehle and Elisabeth Ralfkiaer and Mats Ehinger and Christer Sundstr{\"o}m and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Peter Brown and Erkki Elonen and {Nordic Lymphoma Group}",
note = "{\circledC} 2012 Blackwell Publishing Ltd.",
year = "2012",
doi = "10.1111/j.1365-2141.2012.09174.x",
language = "English",
volume = "158",
pages = "355--62",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Nordic MCL2 trial update

T2 - six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur

AU - Geisler, Christian H

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Jerkeman, Mats

AU - Räty, Riikka

AU - Andersen, Niels S

AU - Pedersen, Lone B

AU - Eriksson, Mikael

AU - Nordström, Marie

AU - Kimby, Eva

AU - Bentzen, Hans

AU - Kuittinen, Outi

AU - Lauritzsen, Grete F

AU - Nilsson-Ehle, Herman

AU - Ralfkiaer, Elisabeth

AU - Ehinger, Mats

AU - Sundström, Christer

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Brown, Peter

AU - Elonen, Erkki

AU - Nordic Lymphoma Group

N1 - © 2012 Blackwell Publishing Ltd.

PY - 2012

Y1 - 2012

N2 - Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at www.isrctn.org as ISRCTN 87866680.

AB - Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin lymphoma entity, with a median survival of about 5 years. In 2008 we reported the early - based on the median observation time of 4 years - results of the Nordic Lymphoma Group MCL2 study of frontline intensive induction immunochemotherapy and autologous stem cell transplantation (ASCT), with more than 60% event-free survival at 5 years, and no subsequent relapses reported. Here we present an update after a median observation time of 6·5 years. The overall results are still excellent, with median overall survival and response duration longer than 10 years, and a median event-free survival of 7·4 years. However, six patients have now progressed later than 5 years after end of treatment. The international MCL Prognostic Index (MIPI) and Ki-67-expression were the only independent prognostic factors. Subdivided by the MIPI-Biological Index (MIPI + Ki-67, MIPI-B), more than 70% of patients with low-intermediate MIPI-B were alive at 10 years, but only 23% of the patients with high MIPI-B. These results, although highly encouraging regarding the majority of the patients, underline the need of a risk-adapted treatment strategy for MCL. The study was registered at www.isrctn.org as ISRCTN 87866680.

KW - Aged

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carmustine

KW - Cyclophosphamide

KW - Cytarabine

KW - Disease-Free Survival

KW - Etoposide

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Immunotherapy

KW - Lymphoma, Mantle-Cell

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Podophyllotoxin

KW - Prognosis

KW - Recurrence

KW - Survival Rate

KW - Transplantation, Autologous

U2 - 10.1111/j.1365-2141.2012.09174.x

DO - 10.1111/j.1365-2141.2012.09174.x

M3 - Journal article

VL - 158

SP - 355

EP - 362

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -

ID: 36545302